IP Library Granted Patent US 8,106,177
Granted Patent B2
US 8,106,177 · App. 13/079,457 · Granted Jan 31, 2012

Nucleic acids encoding human anti-IL-23 antibodies

Assignee: Janssen Biotech, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,106,177
App. No.
13/079,457
Granted
Jan 31, 2012
Kind
B2
Abstract

A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Claims (29)

1. An isolated nucleic acid molecule encoding an IL-23p19 antibody, comprising a light chain variable region nucleotide sequence and a heavy chain variable region nucleotide sequence, said light chain variable region nucleotide sequence encoding:

a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:50;

a CDRL2 amino acid sequence of SEQ ID NO:56; and

a CDRL3 amino acid sequence of SEQ ID NO:73,

said heavy chain variable region nucleotide sequence encoding:

a complementarity determining region heavy chain (CDRH1) amino acid sequence of SEQ ID NO:5;

a CDRH2 amino acid sequence of SEQ ID NO:20; and

a CDRH3 amino acid sequence of SEQ ID NO:44.

2. An isolated nucleic acid vector comprising the nucleic acid molecule according to claim 1 .

3. An isolated host cell comprising the isolated nucleic acid molecule according to claim 1 , wherein the host cell is prokaryotic or eukaryotic.

4. The host cell according to claim 3 , wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, P3X63Ag8.653, and SP2/0-Ag14, myeloma, and lymphoma cells.

5. A method for producing an IL-23p19 antibody, comprising culturing the isolated host cell of claim 3 under conditions such that the IL-23p19 antibody is expressed and recovered.

6. An isolated nucleic acid molecule encoding an IL-23p19 antibody, comprising a light chain variable region nucleotide sequence and a heavy chain variable region nucleotide sequence, said light chain variable region nucleotide sequence encoding a light chain variable region amino acid sequence of SEQ ID NO:116 and said heavy chain variable region nucleotide sequence encoding a heavy chain variable region amino acid sequence of SEQ ID NO:106.

7. An isolated nucleic acid vector comprising one or both of (i) a variable region nucleotide sequence encoding a light chain variable region amino acid sequence of SEQ ID NO:116 and (ii) a variable region nucleotide sequence encoding a heavy chain variable region amino acid sequence of SEQ ID NO:106.

8. An isolated host cell comprising the isolated nucleic acid molecule according to claim 6 , wherein the host cell is prokaryotic or eukaryotic.

9. The host cell according to claim 8 , wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, P3X63Ag8.653, SP2/0-Ag14, myeloma, and lymphoma cells.

10. A method for producing an IL-23p19 antibody, comprising culturing the isolated host cell of claim 8 under conditions such that the IL-23p19 antibody is expressed and recovered.

11. An isolated nucleic acid molecule encoding an IL-23p19 antibody, comprising a light chain variable region nucleotide sequence selected from the group consisting of SEQ ID NOS: 142-144 and a heavy chain variable region nucleotide sequence selected from the group consisting of SEQ ID NOS: 139-141.

12. An isolated nucleic acid vector comprising one or both of (i) a light chain variable region nucleotide sequence selected from the group consisting of SEQ ID NOS: 142-144 and (ii) a heavy chain variable region nucleotide sequence selected from the group consisting of SEQ ID NOS: 139-141.

13. An isolated host cell comprising the isolated nucleic acid molecule according to claim 11 , wherein the host cell is prokaryotic or eukaryotic.

14. The host cell according to claim 13 , wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, P3X63Ag8.653, SP2/0-Ag14, myeloma, and lymphoma cells.

15. A method for producing an IL-23p19 antibody, comprising culturing the isolated host cell of claim 13 under conditions such that the IL-23p19 antibody is expressed and recovered.

16. An isolated nucleic acid vector composition comprising a first isolated vector comprising a nucleotide sequence encoding:

a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:50;

a CDRL2 amino acid sequence of SEQ ID NO:56; and

a CDRL3 amino acid sequence of SEQ ID NO:73, and a second isolated vector comprising a nucleotide sequence encoding:

a complementarity determining region heavy chain (CDRH1) amino acid sequence of SEQ ID NO:5;

a CDRH2 amino acid sequence of SEQ ID NO:20; and

a CDRH3 amino acid sequence of SEQ ID NO:44.

Assignments (2)
MERGER Recorded Jun 28, 2011
From: CENTOCOR, INC.; ORTHO BIOTECH INC.
To: CENTOCOR ORTHO BIOTECH INC.
Reel/Frame 026515/0001 →
CHANGE OF NAME Recorded Jun 28, 2011
From: CENTOCOR ORTHO BIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 026515/0406 →
Continuity (3)
Division 11617503 · Dec 28, 2006
Provisional Application 60754889 · Dec 29, 2005
Related Publication 20110195455A1 · Aug 11, 2011